Filing Details
- Accession Number:
- 0001209191-22-046489
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-17 19:41:42
- Reporting Period:
- 2022-08-15
- Accepted Time:
- 2022-08-17 19:41:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 906709 | Nektar Therapeutics | NKTR | Pharmaceutical Preparations (2834) | 943134940 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1789857 | Jonathan Zalevsky | C/O Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco CA 94158 | Chief R&D Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-15 | 135,000 | $0.00 | 411,399 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2022-08-16 | 10,560 | $4.76 | 400,839 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Common Stock | Acquisiton | 2022-08-15 | 270,000 | $0.00 | 270,000 | $4.91 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 270,000 | 2030-08-14 | No | 4 | A | Direct |
Footnotes
- Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service.
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.
- Stock options were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants.
- Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service.
Billionaire Hedge Funds
